Guidelines for Opioid Use in Cancer Management are Needed, Expert Says

Video

Although opioid use guidelines from the Centers for Disease Control exclude patients with cancer, drug screenings are required that could further contribute to racial disparities.

A 10-fold rise in urine drug screenings for opioid prescriptions from 2007 to 2019 following guidelines from the Centers for Disease control with particular scrutiny towards Black men has troubling implications when considering racial disparities in opioid access for cancer, according to Andrea C. Enzinger, MD.1

Enzinger, assistant professor of medicine at Harvard Medical School and medical oncologist at Dana-Farber Cancer Institute, spoke with CancerNetwork® in an interview about how these data may indicate that racial discrimination plays a part in these disparities despite the prescription opioid epidemic having a more notable impact on white populations.2

Transcript:

There has been a real push to encourage providers to screen patients for substance misuse. In 2016, the Centers for Disease Control issued their guidelines statement on opioid prescribing for chronic non-cancer pain. Those guidelines specifically excluded cancer patients but have been applied anyways.

Those guidelines suggested that every patient who’s being started on opioid therapy undergo baseline and annual urine drug screening. We, in the oncology field, have some guidance and encouragement to use these tests. However, it’s really unclear where their optimal place lies in treatment of patients with cancer.

There are certain populations that should be having this more proactively and there are certain populations like dying patients that should be excluded. We looked at rates and trends of urine drug screens between 2007 and 2019 and found a more than 10-fold rise in urine drug screens, which was really surprising.

Disturbingly, we also saw that Black patients were more likely than White patients to undergo urine drug screening. Black men in particular were the most likely to undergo urine drug screening. For us, we really worry that this may implicate some racial discrimination and that clinicians looking at a Black patient in front of them, particularly a Black man, may perceive their risks to be higher than it really is.

This is notable because the opioid misuse epidemic has impacted White populations more than Black populations, if we’re being honest about it. Those trends and disparities almost run in the opposite of what they should be.

References

  1. Enzinger AC, Ghosh K, Keating NL, et al. Racial and ethnic disparities in opioid access and urine drug screening among older patients with poor-prognosis cancer near the end of life. J Clin Oncol. Published online January 10, 2023. doi:10.1200/JCO.22.01413
  2. Alexander MJ, Kiang MV, Barbieri M. Trends in Black and White opioid mortality in the United States, 1979–2015. Epidemiology. 2018;29(5):707-715. doi:10.1097/EDE.0000000000000858

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content